He hasn't been very active lately because he knows very well that if he will pump to hard again, this message board will get my iron dome against pumpers. I must say that lately he behaved ok so please dont get any pumping ideas into his head.
You said that you made 5000 dollars shorting at 4.90 and covering at 4.70. So the max you could have earnd is 4000 dollars . You are a pathetic lier... get a life for yourself, really. Obsessing over a company is sick. You already promised that you will never post here again and couldn't keep your word, you need to get help.
Look at hznp at the past 12 months and you will be more optimstic. Hznp had a 75m $ mcap and was considered to be on the brinks of death, when all the chips started falling in to place. Same will happen here. S new NDA and new partnerships will take us there.
Is the price still being manipulated? Of course you sold all your short position at 4.65.... you are the greatest investor in the history of the planet.
You are doing great. Undoubtedly you are the greatest investor in the history of the planet.
Following Adasuve administration, patients must be monitored at least once every 15 minutes for signs of bronchospasm for at least one hour. Based on our discussion with physicians, while the REMS programme limits Adasuve usage into an acute medical setting, most of its components will not be significant deterrents for physicians prescribing Adasuve; the requirement for detailed history-taking (including of prior lung diseases) is already standard procedure. The once-daily dosing is also not a barrier, given the therapeutic intent would often be to calm the patient with a rapid-acting drug and then transition them to oral drugs over time. The need to monitor patients for an hour post-dosing should have little effect on patient flow, as the standard-of-care for acute agitation already requires frequent patient monitoring. Of the REMS criteria, we view the requirement for AAM capabilities as being the most likely to affect physician willingness to use Adasuve. While the need for AAM will be a non-issue in an MER department (as equipment and trained staff are already present), some EP facilities will require adding AAM capabilities if they are not in very close proximity to a hospital/MER setting. For such EP facilities, there may be some reluctance among HCPs to learn intubation procedures. Partly mitigating this risk in the US market is that while EP facilities will likely individually encounter more acute agitation cases than an MER in a hospital, there are many more MER units than EP facilities in the US (~4,500 vs ~200), where the need for AAM will not be a concern. The risk of pulmonary effects from existing clinical data appears low and our discussions with physicians suggest that most will not be overly concerned with this risk given the safety data from the Phase III studies (as no patient required AAM). As post-marketing safety data is accumulated, it remains feasible that some aspects of the REMS could be lessened within two to three years. Premium pricing vs established agitation drugs a potential disincentive Adasuve will be priced at a premium level vs existing acute agitation products (Exhibit 8 shows that most currently used drugs cost under $10/dose while Adasuve will be priced at US$75-100/dose). A per-individual drug dose comparison may not capture total treatment cost differences, given that agitation episodes are currently often treated with multiple dose combinations of antipsychotic and benzodiazepine drugs (whereas the majority of treated patients in the Phase III trials only needed a single Adasuve dose to control their agitation), and benzodiazepines often cause over-sedation, prolonging patient stays and increasing indirect costs. Nonetheless, the per-dose cost differential vs Adasuve may pose an initial barrier towards the drug’s penetration, but we believe that hospital pharmacists and administrators will recognise the drug’s indirect cost savings (notably lower likelihood for property damage or patient/staff injury) versus slower-onset or IM drugs as a meaningful treatment advantage. Hence, the high price may curb initial penetration but, as recognition of the speed of onset and ease of administration advantages spread throughout the medical community, we expect the penetration rate to rise.
I dont know what is your average pps, bur I am gussing 15-20$. If you already see this money as burned, just leave it there... you never know. I really think that with the right PR on the upcoming company moves together with a positive market- pps will pop to high teens.
Sometimes you need to fight fire with fire. Ugly, but effective.
I do live in israel, but my "insider" posts were designed to kill off some annoying pumpers, and it worked very well
Mr. King has now a truck load of cheap options and stocks he already purchased some safe time ago. Now it is the time to reveille pipeline advances and new partnerships. By the way, can anyone tell what happens to insulin when it is in crystal form and rapidly heated?